<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2741">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870974</url>
  </required_header>
  <id_info>
    <org_study_id>FPEB</org_study_id>
    <nct_id>NCT00870974</nct_id>
  </id_info>
  <brief_title>A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions</brief_title>
  <acronym>FPEB</acronym>
  <official_title>Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain,&#xD;
      may be a valuable tool in the early detection, understanding, or evaluation of Parkinson&#xD;
      disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum&#xD;
      Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI).&#xD;
&#xD;
      The goal of this study is to assess [18F]F-PEB positron emission tomography (PET) imaging as&#xD;
      a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research&#xD;
      participants and similarly aged healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Informed consent will be obtained for all subjects. All subjects will undergo a screening&#xD;
      evaluation including baseline clinical laboratory testing, a baseline physical and&#xD;
      neurological evaluation and baseline cognitive evaluations. All subjects will undergo&#xD;
      [18F]F-PEB PET imaging. Subjects may also be asked to undergo standard brain MRI to assist in&#xD;
      the analysis of the PET images obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does FPEB reliably represent the known distribution of MGLUR5 in the brain?</measure>
    <time_frame>at completion of scans</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Huntington Disease</condition>
  <condition>Autistic Spectrum Disorders</condition>
  <condition>Fragile X Syndrome</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Assess [18F]FPEB and PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FPEB</intervention_name>
    <description>Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not &gt;10% of 5 mCi limit) of [18F]F-PEB</description>
    <arm_group_label>Assess [18F]FPEB and PET imaging</arm_group_label>
    <other_name>Fluorine-18</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Written informed consent must be obtained For all females of child-bearing potential, a&#xD;
        negative urine or blood pregnancy test on day of [18F]PEB injection.&#xD;
&#xD;
        INCLUSION CRITERIA:&#xD;
&#xD;
        PD subjects:&#xD;
&#xD;
          -  Age 30 years or older.&#xD;
&#xD;
          -  Clinical diagnosis of PD with at least two of three of the cardinal symptoms of PD&#xD;
             (rest tremor, rigidity, bradykinesia)&#xD;
&#xD;
          -  Hoehn and Yahr[35] ≤ 4.&#xD;
&#xD;
        HD subjects:&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Participants have a clinical diagnosis of symptomatic HD with genetic confirmation&#xD;
&#xD;
          -  Subject is able to provide informed consent as judged by the investigator, or assent&#xD;
             can be obtained from the subject and informed consent provided by the appropriate&#xD;
             legal representative or next of kin.&#xD;
&#xD;
        Healthy volunteers should be 18 years of age or older and have a negative history of&#xD;
        neurological or psychiatric illness.&#xD;
&#xD;
        ASD and/or FRAGILE X:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Clinical diagnosis of ASD and/or FXS&#xD;
&#xD;
          -  Diagnosis of FXS based on gene testing or diagnosis of ASD based on DSM-IV criteria&#xD;
&#xD;
        AD subjects:&#xD;
&#xD;
          -  Participants have a positive assessment for dementia of Alzheimer type in accordance&#xD;
             with the DSM-IV-TR and probable AD according to the NINCDS-ADRDA criteria.&#xD;
&#xD;
          -  Participants do not fulfill the ICC criteria for probable DLB, the NINDS-AIREN for&#xD;
             probable vascular dementia, or the Neary criteria for FTD.&#xD;
&#xD;
          -  CDR score of 0.5, 1 or 2.&#xD;
&#xD;
        MCI subjects:&#xD;
&#xD;
          -  Participants must have a complaint of memory loss, objective impairment in at least&#xD;
             one cognitive domain, essentially preserved activities of daily living, and do not&#xD;
             meet diagnostic criteria for AD or other form of dementia. Participants do not fulfill&#xD;
             the ICC criteria for probable DLB, the NINDS-AIREN for probable vascular dementia, or&#xD;
             the Neary criteria for FTD.&#xD;
&#xD;
          -  CDR score of ≤ 0.5.&#xD;
&#xD;
        AD and MCI:&#xD;
&#xD;
          -  Age 50 years or older.&#xD;
&#xD;
          -  MRI brain scan findings that do not reveal changes indicative of stroke and/or&#xD;
             generalized cerebrovascular disease. Exclusion criterion may be waived if, in the&#xD;
             judgment of the investigator (1) vascular dementia is clinically unlikely and (2) the&#xD;
             subject is deemed unable to tolerate the MRI procedure due to claustrophobia, etc.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        PD, HD and ASD and/or Fragile X subjects:&#xD;
&#xD;
          -  Clinically significant abnormal laboratory value and/or clinically significant&#xD;
             unstable medical or psychiatric illness&#xD;
&#xD;
          -  Any disorder that may interfere with drug absorption distribution, metabolism, or&#xD;
             excretion (including significant gastrointestinal surgery).&#xD;
&#xD;
          -  Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal,&#xD;
             hematological, neoplastic, endocrine, alternative neurological, immunodeficiency,&#xD;
             pulmonary, or other disorder or disease.&#xD;
&#xD;
          -  Clinically significant evidence of vascular disease or alternative neurologic disorder&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
          -  Clinically significant abnormal laboratory value and/or clinically significant&#xD;
             unstable medical or psychiatric illness.&#xD;
&#xD;
          -  Any disorder that may interfere with drug absorption distribution, metabolism, or&#xD;
             excretion (including significant gastrointestinal surgery).&#xD;
&#xD;
          -  Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal,&#xD;
             hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or&#xD;
             other disorder or disease.&#xD;
&#xD;
        AD and MCI subjects:&#xD;
&#xD;
          -  The subject has clinically significant abnormal laboratory value and/or clinically&#xD;
             significant unstable medical or psychiatric illness&#xD;
&#xD;
          -  The subject has any disorder that may interfere with drug absorption distribution,&#xD;
             metabolism, or excretion (including significant gastrointestinal surgery).&#xD;
&#xD;
          -  The subject has evidence of clinically significant gastrointestinal, cardiovascular,&#xD;
             hepatic, renal, hematological, neoplastic, endocrine, alternative neurological,&#xD;
             immunodeficiency, pulmonary, or other disorder or disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Russell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>David Russell, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Huntington's</keyword>
  <keyword>Fragile X</keyword>
  <keyword>Autistic Spectrum</keyword>
  <keyword>Alzheimer's</keyword>
  <keyword>MCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

